Kelly A. Conway - Concepedia

Author

Kelly A. Conway

Johnson & Johnson (United States)

Also Known As

K. A. CONWAY, Kelly A Conway, Kelly A. Conway, Kelly Conway

Publications

7.4K

Citations

H-Index

Concepts

All Affiliations

Johnson & Johnson (United States)Brigham and Women's Hospital Harvard University

About

Kelly A. Conway is an author at Johnson & Johnson (United States) specializing in medicine, pharmacology, and alzheimer's disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	4K
2	Natural Sciences	2	2	1.7K
3	Biochemistry	2	2	1.7K
4	Engineering	1	1	29
5	Social Sciences	1	1	781

Kelly A. Conway

Publications

6.9K

Citations

H-Index

Page 1

	Year	Citations
Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy Kelly A. Conway, Seung‐Jae Lee, Jean‐Christophe Rochet, Proceedings of the National Academy of Sciences	2000	1.5K
NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded Paul H. Weinreb, Weiguo Zhen, Anna W. Poon, Biochemistry Protein AssemblyA Protein ImplicatedNeurochemical BiomarkersAlzheimer's DiseaseProtein Folding	1996	1.5K
Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease Kelly A. Conway, James D. Harper, Peter T. Lansbury Nature Medicine Neurodegenerative DiseasesVitro Fibril FormationMolecular BiologyDegenerative PathologyProtein Misfolding	1998	1.5K
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct Kelly A. Conway, Jean‐Christophe Rochet, Robert M. Bieganski, Science	2001	1.1K
Fibrils Formed in Vitro from α-Synuclein and Two Mutant Forms Linked to Parkinson's Disease are Typical Amyloid Kelly A. Conway, James D. Harper, Peter T. Lansbury Biochemistry Typical AmyloidMolecular BiologyMutant FormsSocial SciencesAlzheimer's Disease	2000	781
Inhibition of Fibrillization and Accumulation of Prefibrillar Oligomers in Mixtures of Human and Mouse α-Synuclein Jean‐Christophe Rochet, Kelly A. Conway, Peter T. Lansbury Biochemistry	2000	220
2-Amino-3,4-dihydroquinazolines as Inhibitors of BACE-1 (β-Site APP Cleaving Enzyme): Use of Structure Based Design to Convert a Micromolar Hit into a Nanomolar Lead Ellen W. Baxter, Kelly A. Conway, Ludo Kennis, Journal of Medicinal Chemistry Combinatorial ChemistryDrug TargetChemical BiologyPharmaceutical ChemistryMolecular Pharmacology	2007	145
Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads Yifang Huang, Eric D. Strobel, Chih Y. Ho, Bioorganic & Medicinal Chemistry Letters NanomedicineMedicinal ChemistryEngineeringMedicineRational Drug Design	2010	29
Synthesis of (−)-5,8-Dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene: An Inhibitor of β-Amyloid1–42 Aggregation Michael H. Parker, Robert Chen, Kelly A. Conway, Bioorganic & Medicinal Chemistry β-Amyloid1–42 AggregationMedicinal ChemistryMedicineProtein MisfoldingPharmacology	2002	25
Virus-Based Expression Systems Facilitate Rapid Target In Vivo Functionality Validation and High-Throughput Screening Andrew L. Darrow, Kelly A. Conway, Anil H. Vaidya, SLAS DISCOVERY	2003	11

Page 1